Form 4: Larimar Therapeutics Director Acquires 19,000 Stock Options

Jonathan S. Leff, a director of Larimar Therapeutics, acquired 19,000 stock options on May 29, 2024, according to a recent SEC filing.

Summary

• Jonathan S. Leff, a director at Larimar Therapeutics, acquired 19,000 stock options on May 29, 2024.
• The exercise price of these options is $7.07.
• The options vest on the earlier of May 29, 2025, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 29, 2034.
• Leff disclaims beneficial ownership of the securities, holding the options for the benefit and direction of Deerfield Management Company, L.P.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock option transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock option acquisition by a company director, which is common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates